Inceptua and Portola enter exclusive distribution agreement for Ondexxya®
LUXEMBOURG / SAN FRANCISCO – LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – – Inceptua, a global pharmaceutical company…
Read More Insights
The 21st Century Cures Act (21CCA), which came into effect in February 2017, is intended to help accelerate the development of medicines and bring those medicines to patients more quickly.…
Policies on pre-approval access (‘early access’, ‘expanded access’ etc.) have come into focus since the enactment of the US 21st Century Cures Act. Driven by the requirements of the Act,…
News and Press Releases
LUXEMBOURG / SAN FRANCISCO – LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – – Inceptua, a global pharmaceutical company and service partner and Portola - US developer and manufacturer…
Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling…
NEWTOWN, PA., and LUXEMBOURG, Dec 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with…
